An 83-Year-Old Man with Biochemically Recurrent Metastatic Castration-Sensitive Prostate Cancer

home / case-based-peer-perspectives / an-83-year-old-man-with-biochemically-recurrent-metastatic-castration-sensitive-prostate-cancer

Sheela Tejwani, MD, reviews the case of an 83-year-old man with biochemically recurrent mCSPC and discusses the possible treatment approaches.

Case Presentation: An 83-Year-Old Man with Biochemically Recurrent Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

EP. 1: Case Presentation: An 83-Year-Old Man with Biochemically Recurrent Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Sheela Tejwani, MD
October 13th 2022

Sheela Tejwani, MD, presents the case of an 83-year-old man with mCSPC, and shares her first impressions as compared to her typical patients.

Watch

First-Line Therapy Options for mCSPC

EP. 2: First-Line Therapy Options for mCSPC

Sheela Tejwani, MD
October 13th 2022

Dr Tejwani lists the frontline treatment options currently available for mCSPC and reviews the chosen treatment regimen in the presented patient case.

Watch

Treatment Approaches for Castration-Sensitive Prostate Cancer with Low Volume Metastatic Disease

EP. 3: Treatment Approaches for Castration-Sensitive Prostate Cancer with Low Volume Metastatic Disease

Sheela Tejwani, MD
October 13th 2022

An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.

Watch

Monitoring Patients on Therapy for mCSPC

EP. 4: Monitoring Patients on Therapy for mCSPC

Sheela Tejwani, MD
October 13th 2022

An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.

Watch

Recent Advances in mCSPC and Advice for Community Oncologists

EP. 5: Recent Advances in mCSPC and Advice for Community Oncologists

Sheela Tejwani, MD
October 13th 2022

Sheela Tejwani, MD, highlights some exciting recent trial data and shares clinical pearls for community oncologists treating mCSPC.

Watch